Cargando…
A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviral from the ground up is time intensive. Therefore, most antiviral discovery efforts are focused on the re-purposing of clinical stage or approved...
Autores principales: | Chitalia, Vipul C., Munawar, Ali H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558548/ https://www.ncbi.nlm.nih.gov/pubmed/33059719 http://dx.doi.org/10.1186/s12967-020-02476-9 |
Ejemplares similares
-
dsRNA as broad-spectrum antiviral therapeutics
por: Xu, Congfei
Publicado: (2022) -
Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19
por: Tripp, Ralph A., et al.
Publicado: (2023) -
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
por: Jans, David A., et al.
Publicado: (2020) -
A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes
por: Wojcechowskyj, Jason A., et al.
Publicado: (2010) -
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
por: Jans, David A., et al.
Publicado: (2021)